KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 3.09%.

  • BioNTech SE's EBITDA Margin fell 39300.0% to 3.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.0%, marking a year-over-year increase of 17100.0%. This contributed to the annual value of 47.77% for FY2024, which is 658500.0% down from last year.
  • Per BioNTech SE's latest filing, its EBITDA Margin stood at 3.09% for Q3 2025, which was down 39300.0% from 192.14% recorded in Q2 2025.
  • Over the past 5 years, BioNTech SE's EBITDA Margin peaked at 81.15% during Q1 2021, and registered a low of 750.74% during Q2 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 12.49% (2024), whereas its average is 63.61%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -4148400bps in 2024, then soared by 5586000bps in 2025.
  • Quarter analysis of 5 years shows BioNTech SE's EBITDA Margin stood at 0.0% in 2021, then surged by 90606241bps to 76.97% in 2022, then crashed by -54bps to 35.58% in 2023, then plummeted by -65bps to 12.49% in 2024, then tumbled by -125bps to 3.09% in 2025.
  • Its last three reported values are 3.09% in Q3 2025, 192.14% for Q2 2025, and 292.18% during Q1 2025.